SanguiBioTech Yields Revenues of over USD31,000 in Q2 2015 According to Preliminary Figures
January 28 2015 - 9:00AM
Business Wire
According to preliminary, unaudited figures Sangui Biotech
International, Inc. yielded revenues from royalties and product
sales of more than USD31,000 in the course of the second quarter of
its financial year 2015, ended December 31, 2014. In the first
quarter of the 2015 financial year (ended September 30, 2014)
revenues had amounted to USD73,740; in the second quarter of its
financial year 2014 (ended December 31, 2013) the company reported
revenues of USD33,776. According to those preliminary figures,
revenues in the first six months of the 2015 financial year
amounted to approximately USD105,000 after USD60,303 in the
respective period of the previous year.
Sangui Biotech International, Inc.,
Revenue Development for the 2013 through
2015
Financial Years (per quarter)
Fin. Quarter
USD 2013 Q1 20,549 2013 Q2 27,494 2013 Q3 33,388 2013 Q4 24,056
2014 Q1 26,527 2014 Q2 33,776 2014 Q3 29,438 2014 Q4 43,729 2015 Q1
73,740 2015 Q2 (p) >31,000
Sangui BioTech International, Inc. ("SGBI") is a holding company
the shares of which are being traded on the OTCQB marketplace
(www.otcmarkets.com: SGBI) and the OTC markets of Berlin and
Hamburg-Hannover stock exchanges. Its purpose is to provide
financing and access to the capital markets for the enterprises of
the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary
of Sangui BioTech International, Inc.
Some of the statements contained in this news release discuss
future expectations, contain projections of results of operation or
financial condition or state other “forward-looking” information.
These statements are subject to known and unknown risks,
uncertainties, and other factors that could cause the actual
results to differ materially from those contemplated by the
statements. The forward-looking information is based on various
factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections
include, among many others, the ability of the Company to raise
sufficient capital to meet operating requirements. Words such as
“anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” and variations of such words and similar expressions
are intended to identify such forward-looking statements. Unless
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Sangui BiotechJoachim FleingPhone: +49 (179) 7963472Fax: +49
(2302) 915191e-mail: fleing@sangui.de
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Feb 2024 to Feb 2025